AstraZeneca’s MedImmune has inked a deal with Israeli group Compugen giving it access to the firm’s experimental bi- and multi-specific antibody products.
News
NHS to fund balloon pulmonary angioplasty in the UK
NHS England is funding a pioneering procedure that will improve treatment outcomes for patients with a lung disease called Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
EU reviews for Sanofi’s Dupixent, cemiplimab
European regulators have agreed to review Sanofi and Regeneron’s Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma.
Atopic dermatitis patients to be denied NHS access to Dupixent
The National Institute for Health and Care Excellence has issued draft guidance rejecting Sanofi/Regeneron’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis.
The wait is over! PharmaTimes Clinical Researcher of the Year – The Americas announces finalists
Following a meeting of the executive steering group earlier this month, PharmaTimes Media has been busily contacting each and every entrant to the highly prestigious Clinical Researcher of the Year – The Americas competition to reveal their fate.
International Clinical Researcher of the Year: Book now and enjoy an Early Bird discount
The Awards Ceremony, to be held at the Millennium Gloucester Hotel in London’s Kensington on 17 May, is a must-attend event for anyone in the pharma industry.
Communications Team of the Year opens for entry – with two new categories
PharmaTimes Communications Team of the Year has a long history of being the only pharma industry award that tests the competencies and potential of communications agency teams, benchmarking talent agency side. Such is the popularity of the competition that the decision has been taken to increase the number of categories and with it, the opportunity for agencies – and individuals – to shine.
Research backs halving chemo after bowel cancer surgery
Some patients receiving chemotherapy after surgery for bowel cancer might only need three months of treatment rather than the six months currently given, according to new research published in Lancet Oncology.
EU ready to review Shire’s lanadelumab for HAE
EU regulators have validated Shire’s application to market its experimental hereditary angioedema (HAE) drug lanadelumab, indicating that there is sufficient data to begin a priority review.
EMA to review Sanofi’s type I diabetes therapy
The European Medicines Agency has accepted for review Sanofi’s experimental type I diabetes therapy sotagliflozi.
Takeda eyes up Shire
Takeda has revealed that it is considering making a move on Shire to add ballast to its core therapeutic areas.
PharmaTimes Marketer of the Year 2018 is open for entry!
Designed to assess and reward the competencies and potential of pharma marketers and aspiring marketers, the prestigious PharmaTimes Marketer of the Year competition identifies and benchmarks marketing talent within pharma organisations, against the wider industry. The competition, which this year celebrates its 25th anniversary is now open for entry and marketers at all levels of their career are invited to enter.
NHS England, NHS Improvement reveal plans for collaboration
NHS England and NHS Improvement have revealed their intention to work much more closely together to maximise efficiencies and reduce duplication.
Final NICE green light for Ipsen’s Cometriq
Ipsen’s Cometriq can now be routinely funded by the NHS to treat patients with medullary thyroid cancer (MTC) in England and Wales.
Lords call for clarity on EU healthcare deal
The House of Lords EU Committee is urging the government to clarify the reciprocal healthcare arrangements for UK citizens in the EU and EU citizens in the UK post Brexit.
